The use of combination therapies in the acute management of migraine

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 3, 2006, Pages 293-297

  Krymchantowski, Abouch Valenty ^a,b,c  

^a Headache Center of Rio   (Brazil)

^b Instituto de Neurologia Deolindo Couto   (Brazil)

^c NONE   (Brazil)

Author keywords

Acute treatment; Combination; Migraine; Naproxen; Sumatriptan

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIMIGRAINE AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; ERGOT DERIVATIVE; KETOROLAC; LYSINE ACETYLSALICYLATE; METOCLOPRAMIDE; NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RIZATRIPTAN; ROFECOXIB; SUMATRIPTAN; TOLFENAMIC ACID; TRIMEBUTINE MALEATE; TRIPTAN DERIVATIVE;

ALLODYNIA; ANALGESIA; BOLUS INJECTION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; HEADACHE; HUMAN; MIGRAINE; NAUSEA; PHOTOPHOBIA; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33750029353     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.3.293     Document Type: Review

References (28)

1. Bates D, Ashford E, Dawson R, et al. 1994. Subcutaneous sumatriptan during the migraine aura. Neurology, 44:1587-92.
2. Brandes J, O'Carroll PC, Mannix L, et al. 2005. Therapeutic clinical benefits of a new single-tablet formulation of sumatriptan formulated with RT technology and naproxen sodium [abstract]. Cephalalgia, 25:860.
3. Burstein R, Levy D, Collins B, et al. 2005. Therapeutic approach to migraine with allodynia [abstract]. Neurology, 64(Suppl 1):A151.
4. Dahlof CG 1995. How does sumatriptan perform in clinical practice? Cephalalgia, 15(Suppl 15):21-8.
5. Dodick DW. 2001. Acute and prophylactic management of migraine. Clin Cornerstone, 4:36-52.
6. Ferrari MD, Goadsby PJ, Roon KI, et al. 2002. Triptans, (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia, 22:633-58.
7. Goadsby PJ, Lipton RB, Ferrari MD. 2002. Migraine - Current understanding and treatment. N Engl J Med, 346:257-70.
8. [ICHD-II] Headache Classification Subcommittee of the International Headache Society. 2004. The International Classification of Headache Disorders. 2nd ed. Cephalalgia, 24(Suppl 1):1-160.
9. Krymchantowski AV, Adriano M, Fernandes D. 1999. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia, 19:186-7.
10. Krymchantowski AV. 2000. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr, 58:428-30.
11. Krymchantowski AV, Barbosa JS. 2002. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia, 22:309-12.
12. Krymchantowski AV, Bigal ME, Moreira PF. 2004. Rizatriptan vs. rizatriptan plus rofecoxib vs. rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurology, 28:4(10).
13. Krymchantowski AV, Bigal ME, Moreira PF. 2005. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study [abstract]. Neurology, 64(Suppl 1):A348.
14. Lance JW. 1981. Headache. Ann Neurol, 10:1-10.
15. Lipton RB, Hamelsky SW, Dayno JM. 2002. What do patients with migraine want from acute migraine treatment? Headache, 42(Suppl 1):3-9.
16. Lipton RB, Stewart WF. 1997. Prevalence and impact of migraine. Neurol Clin, 15:1-13.
17. [OSAM] The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. 1992. A Study to Compare Oral Oral Sumatriptan with Oral Aspirin plus Metoclopramide in the Acute Treatment of Migraine. Eur Neurol, 32:177-84.
18. Peroutka SJ. 1998. Beyond monotherapy: Rational polytherapy in migraine. Headache, 38:18-22.
19. Rasmussen BK. 1995. Epidemiology of headache. Cephalalgia, 15:45-68.
20. Smith TR, Sunshine A, Stark SR, et al. 2005. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache, 45:983-91.
21. Stewart WF, Schechter A, Lipton RB. 1994. Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology, 44(Suppl 4):S24-39.
22. Stewart WF, Lipton RB, Simon D. 1996. Work-related disability: results from the American migraine study. Cephalalgia, 16:231-8.
23. Tfelt-Hansen P, Henry P, Mulder LJ, et al. 1995. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet, 346:923-6.
24. Tfelt-Hansen P, Lipton RB. 1993. Prioritizing treatment. In Olesen J, Tfelt-Hansen P, Welch KMA (eds). The Headaches. New York: Raven Press. p 359-62.
25. Ttelt-Hansen P, Welch KMA. 2000. General principles of pharmacological treatment of migraine. In Olesen J, Tfelt-Hansen P, Welch KMA (eds). The Headaches. 2nd ed. Philadelphia (PA): Lippincott Willians & Wilkins. p 385-9.
26. Visser WH, de Vriend RH, Jaspers NHWM, et al. 1996a. Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache, 36:471-5.
27. Visser WH, de Vriend RH, Jaspers NHWM, et al. 1996b Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology, 47:46-51.
28. Wilkinson M. 1983. Treatment of the acute migraine attack-current status. Cephalalgia, 3:61-7.